Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the pharma company continues to expand its capabilities in artificial ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a partnership with Juvena Therapeutics to develop new muscle-boosting drugs.

Eli Lilly and Co. and Purdue Strategic Ventures recently participated in a $12 million funding round to support a new remote lab platform aimed at significantly decreasing the time it takes to ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing Consortium aimed at pioneering new advances in how medicines are produced.

Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases ...

Eli Lilly & Company (NYSE:LLY) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential. Bernstein SocGen Group reaffirmed its Outperform rating and $1,100 price ...

We're also seeing new funds spring up that promise to drive market interest for AI in healthcare even further, including a new $500 million biotech ecosystem fund from Eli Lilly LLY ...

Organovo Holdings, Inc. announced that it will be acquired by Eli Lilly and Company, which includes Organovo's FXR program and its lead asset, FXR314, aimed at treating inflammatory bowel disease ...

Eli Lilly and Company’s share was trading at $798.89 as of July 23 rd. LLY’s trailing and forward P/E were 65.00 and 36.63 respectively according to Yahoo Finance.